• Internal medicine · Dec 2024

    Co-occurrence of Neuromyelitis Optica Spectrum Disorder and Idiopathic Multicentric Castleman Disease Successfully Treated with Tocilizumab: A Case Report.

    • Takuma Tsuzuki Wada, Kazuhiro Yokota, Mariko Okada, Takaya Ichimura, Takehito Ueno, Nobuhito Okumura, Iichiro Osawa, Kaiji Inoue, Yuji Akiyama, Yoshihiko Nakazato, Atsushi Sasaki, Toshimasa Yamamoto, and T... more oshihide Mimura. less
    • Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan.
    • Intern. Med. 2024 Dec 26.

    AbstractWe herein report a 52-year-old woman with anti-aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) and idiopathic multicentric Castleman disease (iMCD) who was successfully treated with tocilizumab, a humanized anti-human interleukin (IL)-6 receptor monoclonal antibody. This is the first report of a case of coexisting NMOSD and iMCD. IL-6 is involved in the pathogenesis of both NMOSD and iMCD, and tocilizumab is effective against both diseases. By treating the patient with tocilizumab, the lung lesions due to iMCD improved, and the neurological symptoms of NMOSD did not recur.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.